AstraZeneca US Arm to Sell Rare Disease Drugs in More Countries

AstraZeneca PLC hopes to double the number of countries where Alexion, its US biotech arm, sells its rare disease drugs, the Financial Times reported.

The company aims to sell its products in 100 countries by 2025 to 2030, Marc Dunoyer, Alexion’s chief executive and AstraZeneca’s former chief financial officer, told the newspaper in an interview.

Alexion scientists are also working with AstraZeneca to develop new treatments for conditions with far larger patient populations, including a pill for the eye disease geographic atrophy, an advanced form of age-related macular degeneration, according to the report.

AstraZeneca has said its 2021 ...